Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0GKHFY
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CD30-BTG-ADC
|
|||||
| Synonyms |
Bacterial transglutaminase-antibody drug conjugates (Innate Pharma/ETH Zurich); BTG-ADC
Click to Show/Hide
|
|||||
| Organization |
Innate Pharma SA
|
|||||
| Drug Status |
Terminated
|
|||||
| Indication |
In total 1 Indication(s)
Cutaneous mesenchymal large cell lymphoma [ICD11:2B00]
Terminated
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-CD30 mAb cAC10Q
|
Antibody Info | ||||
| Antigen Name |
Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
PEG3-benzotriazole-PEG-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
The cAC10Q variant of antibody cAC10 has two acceptor glutamines per heavy chain at amino acid residues mutations, N295Q and N297Q. Bacterial transglutaminase (BTG) was exploited to site-specifically conjugate linker-payload to the glutamine at positions 295 and 297 of cAC10.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.